Does Intravitreal Injection of Triamcinolone Acetonide Impairs the Adrenal Function

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

28 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-04-30

Study Completion Date

2008-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The use of intravitreal corticosteroids in the management ocular inflammatory diseases has recently gained widespread acceptance. The purpose of this study is to determine if the use of intravitreal triamcinolone is associated with suppression of endogenous cortisol production, as generally admitted for patients treated with oral or parenteral corticosteroid therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Local Triamcinolone Injection in Active Thyroid Orbitopathy

NCT01280214

Thyroid Disease

UNKNOWN NA

Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases

NCT05337332

Central Serous Chorioretinopathy Irvine-Gass Syndrome Pars Planitis +1 more

UNKNOWN PHASE2/PHASE3

Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis

NCT01789320

Uveitis Intermediate Uveitis Posterior Uveitis +2 more

COMPLETED PHASE1/PHASE2

The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy

NCT01579539

Thyroid-associated Ophthalmopathy Dry Eye Syndrome

COMPLETED PHASE3

A Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers

NCT00134992

Healthy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The normalcy of hypothalamic- pituitary- adrenal axis (HPA axis) of enrolled subjects will will be assessed before intravitreal injection of 4mg of triamcinolone and again after one day, one week and two weeks. Patients with abnormal HPA axis will be re-tested after four weeks and later until the HPA axis function return to normal. The HPA axis will be assessed with low dose (1mcg) intravenous corticotropin(ACTH) stimulation test, in which cortisol levels will be sampled before , 30 minutes and 60 minutes after 1mcg ACTH IV injection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Secondary Adrenal Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients receiving intravitreous injection of triamcinolone 4mg

Exclusion Criteria

* patients receiving steroids in any form, except by intravitreous administration

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

avraham ishay

Dr

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Avraham Ishay, MD

Role: PRINCIPAL_INVESTIGATOR

Haemek Medical Center , Endocrine Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Haemek Medical Center

Afula, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

002507EMC

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

NCT00833495 COMPLETED PHASE2

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

NCT00689078 COMPLETED PHASE4

TLR-9 Antagonism in Steroid Resistant Optic Neuritis

NCT01424735 COMPLETED NA

Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator

NCT02798289 COMPLETED NA

Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in Dry Eye Disease

NCT03827564 TERMINATED NA

Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis

NCT01120132 COMPLETED PHASE2

Steroid Eye Drops in Chronic Central Serous Chorioretinopathy

NCT05633576 RECRUITING PHASE3

Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax

NCT04555694 COMPLETED PHASE4

Topical Steroid Treatment For Dry Eye

NCT02218827 UNKNOWN NA

Povidone-iodine 2% Eye Drop Versus Artificial Tear Drop for Treatment of Adenoviral Keratoconjunctivitis

NCT04041856 UNKNOWN PHASE1/PHASE2

Clinical Study to Evaluate Tear Characteristics Following Acute TrueTear™ Use

NCT03274999 TERMINATED NA

Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work

NCT07266948 RECRUITING PHASE4

The Influence of PRN Dry Eye Omega-3 Nutritional Regimen on Tear Osmolarity In Cases Of Dry Eye Disease

NCT02260960 COMPLETED PHASE2/PHASE3

Evaluating the Efficacy of Dry Eye (DE) Disease Treatment Using Novel Tear Film Imager (TFI)

NCT04670263 COMPLETED PHASE2/PHASE3

Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease

NCT04936854 RECRUITING PHASE2

Multicenter Trial Evaluating Quality of Tears Produced by Nasal Neurostimulation

NCT02385292 COMPLETED NA

Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment

NCT03097614 COMPLETED NA

A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome

NCT02680158 COMPLETED NA

Multicenter Uveitis Steroid Treatment (MUST) Trial

NCT00132691 COMPLETED PHASE4

Assessment of the Efficacy of Ocular Dipyridamole in the Treatment of Dry Eye Symptomology in Subjects With Pterygium

NCT02782260 UNKNOWN PHASE2

Effect of Topical Glaucoma Therapy on Tear Film Stability in Healthy Subjects

NCT01746602 TERMINATED PHASE3

Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model

NCT01730872 COMPLETED PHASE4

IPL and MGX Versus MGX Alone in the Treatment of Dry Eye Disease Secondary to MGD

NCT03265652 COMPLETED NA

Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator

NCT02526290 COMPLETED NA

Moderate-to-Severe Dry Eye Disease Relief Using Acoltremon

NCT07268599 ENROLLING_BY_INVITATION